Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs

A formulation of paclitaxel encapsulated in a liposome, wherein the liposome comprises a lipid fraction, and the lipid fraction comprises 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), tetramyristoyl cardiolipin (CL) and cholesterol (CH), wherein the DOPC comprises between about 90 percent to about 92 percent of the lipid fraction, wherein the amount of the lipid fraction is at least about 3.5% w/v of the formulation and not more than about 8.5% w/v of the formulation, and wherein the liposomes have a mean size of 50 to 200 nm, and wherein said formulation is stable in an aqueous solution at room temperature for at least three days.